Golotimod

Summary

Golotimod is an investigational immunomodulatory peptide, structurally related to the thymic peptide thymopentin. It is being explored as a potential therapeutic agent for inflammatory and oncologic conditions, notably ulcerative colitis and head‑and‑neck cancer, based on early computational studies. The compound can be administered orally or by subcutaneous injection, but it remains experimental and has not received regulatory approval for any indication.

Mechanism of Action

Golotimod is a synthetic analog of thymopentin, a short peptide derived from the thymus that influences T‑cell differentiation and cytokine release. While the precise molecular targets of Golotimod have not been defined in published studies, its classification as an immunomodulatory peptide suggests it may interact with immune‑regulatory pathways, potentially modulating Th1/Th2 balance or enhancing innate immune signaling. The peptide’s activity is presumed to arise from binding to surface receptors on lymphocytes or dendritic cells, leading to downstream signaling cascades that alter immune responses.

What the Research Shows

Computational analyses have identified Golotimod as a candidate for repurposing in two disease areas. In a 2025 bioinformatic study of ulcerative colitis, molecular docking predicted Golotimod to bind favorably to disease‑relevant targets, ranking it alongside Apremilast as a promising therapeutic lead. Separately, a 2026 genomics‑driven drug‑repurposing pipeline (GARD) applied to head‑and‑neck cancer highlighted Golotimod among emerging candidates, based on significant associations between its known protein interactions and cancer‑linked genomic alterations. Both investigations relied on in silico methods—docking and network‑based gene‑drug mapping—and did not include experimental validation in cells, animals, or patients.

Reported Benefits

Preliminary in silico work suggests Golotimod may possess anti‑inflammatory activity useful in ulcerative colitis and could modulate pathways implicated in head‑and‑neck tumor biology. Its classification as an immunomodulatory peptide raises the possibility of enhancing immune surveillance or correcting dysregulated cytokine networks, which are central to both conditions. These potential advantages are derived solely from computational predictions and have not yet been demonstrated in laboratory or clinical settings.

Limitations of the Evidence

The current evidence for Golotimod is limited to computational docking and network‑based drug‑repurposing analyses; no preclinical efficacy, pharmacokinetic, or safety data have been reported. The lack of experimental validation means the predicted target interactions may not translate into biological activity. Additionally, the peptide’s exact mechanism, optimal dosing, and therapeutic window remain undefined, and regulatory approval has not been obtained. Consequently, its clinical usefulness remains speculative.

Safety Considerations

Safety information for Golotimod is not available in the published literature. As an investigational peptide, its tolerability, immunogenicity, and potential off‑target effects have not been characterized in humans or animal models. Until systematic toxicology and phase‑I studies are performed, the risk profile cannot be defined, and use should be confined to controlled research settings. Caution is warranted when considering any off‑label or unsupervised administration.

How It Is Administered

Golotimod can be delivered orally or by subcutaneous injection, reflecting its peptide nature and potential for systemic exposure. Formulation details, such as dosage form or concentration, have not been disclosed in the available sources. Administration routes are described only in the context of investigational use; no approved product or commercial preparation exists.

Routes of Administration

Goals & Uses

• Adjunct treatment of tuberculosisInfectious DiseaseModerate
• Oral mucositis preventionOncology Supportive CareLow
• Immune restoration in immunocompromised patientsImmunologyLow
• Hepatitis C treatment supportInfectious DiseaseLow

Contraindications

• Autoimmune conditions (active)AutoimmuneModerate
• Known hypersensitivity to golotimod or componentsAllergyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Gastrointestinal discomfortGastrointestinalUncommon
• FatigueGeneralUncommonLow energy or tiredness
• FeverSystemicUncommonElevated body temperature

Drug Interactions

• Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
• Antitubercular agents (e.g., rifampicin, isoniazid)Low

Population Constraints

• Severe renal or hepatic impairmentOrgan FunctionRelative
• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; clinical trials conducted in Eastern Europe and Russia
• United StatesInvestigationalInvestigated under IND; not FDA approved for any indication
• United KingdomUnknownNo known MHRA approval; status not clearly defined

Not approved by FDA, EMA, or other major regulatory agencies. Studied under investigational new drug (IND) status in clinical trials. Developed by SciClone Pharmaceuticals and related entities.

Evidence & Sources

• Integrative Bioinformatics Analysis Reveals Key Regulatory Genes and Therapeutic Targets in Ulcerative Colitis Pathogenesis
  Journal ArticleLowRahman SA, et al.2025-01-01T00:00:00.000000Z
• GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation
  Journal ArticleLowTanikella P, et al.2026-01-01T00:00:00.000000Z
• GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation
  Journal ArticleLowTanikella P, et al.2026-01-01T00:00:00.000000Z
• Discontinued drugs in 2012 - 2013: hepatitis C virus infection
  Journal ArticleLowGentile I, et al.2015-01-01T00:00:00.000000Z

Frequently Asked Questions